β-<4-(4'-hydroxyphenoxy)-3,5-diiodophenyl>-α-methylpropionic acid | 35456-54-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: β-<4-(4'-hydroxyphenoxy)-3,5-diiodophenyl>-α-methylpropionic acid
• 英文别名: 3-[4-(4-Hydroxyphenoxy)-3,5-diiodophenyl]-2-methylpropanoic acid
• CAS: 35456-54-3
• 化学式: C₁₆H₁₄I₂O₄
• 分子量: 524.094
• InChiKey: BODJSHHDZMIKKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  β-<4-(4'-hydroxyphenoxy)-3,5-diiodophenyl>-α-methylpropionic acid 在 ammonium hydroxide 、 碘 作用下， 以 甲醇 为溶剂， 以100%的产率得到α-methyl-3,5,3',5'-tetraiodothyropropionic acid
  参考文献：
  名称：

  .alpha.-Methylated analogs of triiodothyroalkanoic acids: synthesis and biological activity

  摘要：

  Three novel thyroid hormone analogues: alpha-methyl-3,5,3'-triiodothyroacetic acid, alpha-methyl-3,5,3'-triiodothyropropionic acid, and alpha-methyl-3,5,3',5'-tetraiodothyropropionic acid were synthesized. The hepatic thyroid receptor affinity of these analogues was compared to that other available thyroid analogues. The ability of these compounds to increase the activity of two hepatic enzymes and to lower blood cholesterol was compared to that of L-triiodothyronine. alpha-Methyl-3,5,3'-triiodothyroacetic acid was shown to have less nuclear binding affinity, less enzyme inducing ability, but more blood cholesterol lowering ability than triiodothyroacetic acid. alpha-Methyl-3,5,3',5'-tetraiodothyropropionic acid showed less nuclear binding affinity and less enzyme-inducing activity than alpha-methyl-3,5,3'-triiodothyropropionic acid.

  DOI：

  10.1021/jm00081a017
• 作为产物：
  描述：

  β-(3,5-diiodo-4-hydroxyphenyl)-α-methylpropionic acid 在 氢碘酸 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 28.0h， 生成 β-<4-(4'-hydroxyphenoxy)-3,5-diiodophenyl>-α-methylpropionic acid
  参考文献：
  名称：

  .alpha.-Methylated analogs of triiodothyroalkanoic acids: synthesis and biological activity

  摘要：

  Three novel thyroid hormone analogues: alpha-methyl-3,5,3'-triiodothyroacetic acid, alpha-methyl-3,5,3'-triiodothyropropionic acid, and alpha-methyl-3,5,3',5'-tetraiodothyropropionic acid were synthesized. The hepatic thyroid receptor affinity of these analogues was compared to that other available thyroid analogues. The ability of these compounds to increase the activity of two hepatic enzymes and to lower blood cholesterol was compared to that of L-triiodothyronine. alpha-Methyl-3,5,3'-triiodothyroacetic acid was shown to have less nuclear binding affinity, less enzyme inducing ability, but more blood cholesterol lowering ability than triiodothyroacetic acid. alpha-Methyl-3,5,3',5'-tetraiodothyropropionic acid showed less nuclear binding affinity and less enzyme-inducing activity than alpha-methyl-3,5,3'-triiodothyropropionic acid.

  DOI：

  10.1021/jm00081a017

文献信息

• FOOD OR BEVERAGE COMPOSITION FORTIFIED WITH THYRONAMINES AND/OR THYRONAMINE PRECURSORS
  申请人：Ehrenkranz Joel R.L.

  公开号：US20110070291A1

  公开（公告）日：2011-03-24

  Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing T2, T1AM, and/or T0AM in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of T2, T1AM, and/or T0AM in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being.
• NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF
  申请人：NanoPharmaceuticals LLC

  公开号：US20140314665A1

  公开（公告）日：2014-10-23

  Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
• US8668926B1
  申请人：——

  公开号：US8668926B1

  公开（公告）日：2014-03-11
• US9750709B2
  申请人：——

  公开号：US9750709B2

  公开（公告）日：2017-09-05